Pfizer's PARP, androgen inhibitors next combo partners for NKTR-214

Pfizer Inc. (NYSE:PFE) will combine NKTR-214 from Nektar Therapeutics Inc. (NASDAQ:NKTR) with the pharma's marketed drugs Xtandi enzalutamide, Talzenna talazoparib and Bavencio avelumab to treat prostate cancer, testing the biotech's hypothesis that stimulation of IL-2 alongside these other MOAs in tumors with a high mutational burden could provide synergistic benefits.

Financial terms for the clinical collaboration are not disclosed, but Pfizer will test triplet combinations of NKTR-214 with anti-PD-L1 drug Bavencio and either Talzenna or Xtandi in metastatic castration-resistant prostate cancer (mCRPC)...